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Morbid obesity in a young woman affected by advanced
chronic kidney disease: an exceptional case report. Does a high
dose of essential amino acids play a key role in therapeutic
success?
S Caria1, S Murtas1, G Loria2, FS Dioguardi3, R Secci1 and P Bolasco1
A 38-year-old woman, obese (219 kg), diabetic, hypertensive, chronic kidney disease (CKD) stage 4, with low plasma albumin level
(2.9 g dl− 1) and marked proteinuria (22 g per day) was studied. Given the advanced-stage CKD with nephrotic proteinuria, we
supplemented low-protein diet with high doses of a tailored essential amino acid mixture (AAs: 44 g per day) to improve weight
reduction in the patient. After 20 months of conservative therapy, the patient lost 43 kg; despite two episodes of infection, albumin
plasma levels increased up to 3.7 g per day. After a further 20 months of dialysis, the patient maintained a diet of 1800 kcal
supplemented with 32 g of AAs and lost 47 kg, whereas both albumin (3.89 ± 0.12 g dl− 1) and C reactive protein returned to
normal. During the follow-up period, anemia improved, erythropoietin was thus discontinued and insulin requirement decreased to
105 IU. This therapeutic option may be beneﬁcial in advanced CKD patients with obesity and diabetes resulting from malnutrition.
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INTRODUCTION
Diabetic patients with a body mass index (BMI) 435 kg m−2
feature a seven-fold higher risk of developing chronic kidney
disease (CKD) and hypertensive patients a six-fold higher risk.1
The predictive power of abdominal obesity for progression of
kidney failure and onset of cardiovascular events is particularly
strong;2,3 in patients in dialysis it is also associated with a high risk
of death.4
We report the case of a young woman affected by severe badly
nourished obesity, diabetes, arterial hypertension and advanced
CKD. Moreover, we highlight the peculiarity of the measures
adopted in clinical, diagnostic and therapeutic management.
CASE REPORT
The patient had been affected by abdominal obesity since
childhood, reaching a weight of 110 kg during puberty. At the
age of 16 years, she went on a high-protein diet with
amphetamine supplements and lost 50 kg. Over the following
years, she attempted a series of diets and underwent implantation
of a gastric balloon. However to no avail, as she progressively
gained weight.
The patient, affected by arterial hypertension, insulin-
dependent type 2 diabetes, diabetic retinopathy and Hashimoto’s
thyroiditis, came to our observation in October 2011, at the age of
38 years, for CKD stage 4 with glomerular ﬁltration rate (GFR)
21 ml min−1, serum creatinine (sCr) 3.9 mg dl− 1, blood urea
nitrogen (BUN) 53 mg dl− 1, abdominal obesity (219 kg, waist
circumference 190 cm, hip circumference 180 cm), BMI 81 kg m−2,
nephrotic proteinuria (22 g per day), hypoalbuminemia
(2.9 g dl− 1), dyslipidemia and secondary hyperparathyroidism
(SHPT) (Table 1). sCr levels were normal until 2007 (0.8 mg dl).
To exclude other causes of renal diseases an immunological panel
examination was performed, revealing negative ﬁndings. Renal
biopsy could not be carried out, as the kidneys were embedded in
an extensive layer of thick fat. Hypothyroidism was successfully
managed with levothyroxine, and cardiac ejection fraction was
normal (60%). The patient had poor blood pressure control
(200/110 mm Hg), therefore antihypertensive therapy was
increased by supplementing the angiotensin-converting-enzyme
inhibitor with calcium channel blockers, β-blockers, doxazosin and
angiotensin receptor blockers; the latter were also added to
enhance the anti-proteinuric effect. Statins could not be
administered due to intolerance. Although glycated hemoglobin
(HbA1c) level was normal (Table 1), glycemic control was poor, the
patient was therefore given high doses of insulin: 130 IU. Given
the advanced CKD, a low-protein diet (LPD) was suggested; the
patient refused to follow a very low-protein diet, but agreed to an
LPD: by food intake recall, it was revealed that the patient was
introducing 2700 kcal per day, and consequently caloric intake
was reduced by 500 kcal.5,6 The diet consisted of the following:
carbohydrates 58%, lipids 32%, proteins 10%, phosphorus 895 mg,
sodium 752 mg and potassium 2100 mg. In view of the
inadequacy of nutrition, advanced CKD, nephrotic proteinuria
and insulin resistance, and with the aim of increasing weight loss,
we ﬁnally supplemented the diet with high doses of AAs: one
sachet of special AAs mixture (4 g: L-Leucine 1250 mg, L-Lysine
650 mg, L-Isoleucine 625 mg, L-Valine 625 mg, L-Threonine
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350 mg, L-Cistine 150 mg, L-Histidine 150 mg, L-Phenyl-alanine
100 mg, L-Methionine 50 mg, L-Tyrosine 30 mg and L-Tryptophan
20 mg (Aminotroﬁc, Errekappa Euroterapici, Milano, Italy) per
20 kg of actual body weight. The singular composition of this AAs
mixture was determined in a particular stoichiometric ratio, and
contained all essential amino acids and two non-essential amino
acids (tyrosine and cysteine).
At this point, although the patient was able to manage her
personal needs, she was only able to walk a few meters unaided.
Table 1 shows the outcome of laboratory examinations over a
period of 40 months. Figure 1 took into account the following
anthropometric parameters: body weight, BMI, circumference of
the arm, and circumference of the hip and waist.7 The patient
began taking a dietary supplement of 44 g AAs divided into four
daily doses in November 2011 (baseline). Within 3 months, the
patient lost 10 kg, although her kidney function was stable (sCr
3.6 mg dl− 1, BUN 40 mg dl− 1 and GFR 24 ml min− 1). Following
these results, the patient was strongly motivated to continue
losing weight and in February 2012 (4th month) because of
progressive respiratory failure with hypoxia and need to evaluate
cardiovascular risk, the patient was admitted to hospital and
started on low-calorie enteral nutrition (EN) via a nasal feeding
tube to increase the speed of weight loss: 2000 ml of liquid
per day, 56 g of AAs per day, electrolyte and vitamin supplements,
and no food intake. Within 10 days, she lost 21 kg while her kidney
function remained stable: sCr 3.3 mg dl− 1, BUN 36 mg dl− 1, GFR
24 ml min− 1, proteinuria/24 h 16 g, plasmatic bicarbonate level 22
mEq l− 1 and albumin level 3.0 g dl− 1. Because of a condition of
respiratory insufﬁciency, continuous O2 therapy was also
prescribed. When EN was stopped, the patient restarted a
supplemented LPD. In the 5th and the 15th months, the patient
presented with a complication in the form of an infected ulcer in
the ﬁrst toe of her left foot, which was treated with protracted
antibiotic therapy, but was resulted in persistently high CPR levels.
In the 15th month O2 therapy was discontinued due to the
resolution of respiratory insufﬁciency. After 20 months of
conservative therapy, the patient had lost a total of 43 kg
(Figure 1), and despite the persistent increase in C reactive
protein (CRP), albumin levels gradually improved to 3.7 g dl− 1
(Table 1). In the 20th month, due to worsening of kidney
functions, the patient started hemodialysis (HD), particularly to
correct peripheral edemas and poorly controlled treatment-
resistant arterial hypertension. During hemodialysis the patient’s
diet was changed and protein-free products removed, although it
continued to be supplemented with AAs (32 g per day, reduced
depending on the weight reached: 176 kg): 1800 kcal, carbohy-
drates 53%, lipids 30%, proteins 17%, phosphorus 900 mg,
potassium 2200 mg and sodium 1462 mg. After the ﬁrst 3 months,
the patient received a 3 weekly bicarbonate diffusive HD without
acetate for 15–16 h per week. Satisfactory dialysis efﬁciency (eKT/V
0.8 ± 0.1) could not be reached due to the high body surface of the
patient, nevertheless a good metabolic balance and nutritional
status were achieved (Table 1); after 20 months of dialysis, the
patient had lost a further 47 kg and reached a weight of 129 kg.
The patient referred to being anuric accordingly, equilibrated
protein catabolic rate was calculated based on the actual weight
of the patient, and was found to be stable: 1.0 ± 0.2 g kg− 1 per
day.8 Throughout the observation period, bicarbonate level
was normal.
DISCUSSION
The patient lost a total of 90 kg over a 40-month follow-up period,
with a ΔBMI of 33.3 kg m−2, her waist circumference decreased by
56 cm, arm circumference by 14 cm and hip circumference 27 cm;
albumin levels increased from 2.9 to 3.8 g dl− 1, her insulin
requirement decreased by 105 IU and the patient maintained a
good metabolic balance over time (Table 1; Figure 1). The patient’s
diet was reduced from 2200 kcal of the conservative phase to
1800 kcal in HD; in our opinion, this kcal reduction alone was not
Table 1. Outcome of nutritional and functional parameters
Baseline 6th
month
12th
month
18th
month
Start HD 20th
month
24th month
HD
30th month
HD
36th month
HD
40th month
HD
Crs (mg dl− 1) 3.9 3.2 3.9 5.7 6 6.5 6.9 8 9.7
BUN (mg dl− 1) 53 61 66 74 88 85 82 80 80
GFR (ml min− 1)a 21 18.5 15 13.5 13 — — — —
eGFR (ml min− 1)b 13.8 17.5 13.7 8.65 8.13 — — — —
eGFR (ml min− 1)c 13.7 17.2 13.7 8.8 8.3 — — — —
Proteinuria (g per day) 22 13 12 10 8 — — — —
Potassium (mmol l− 1) 6.1 5.5 4.8 5 4.6 4.4 4.2 4.8 5.3
Calcium (mg dl− 1) 8.8 9.6 9.7 8.84 9.2 8.86 8.9 8.7 8.86
Phosphorus (mg dl− 1) 4.7 3.8 4.2 4.4 5.5 5.3 5.4 5 3.9
PTH (ρg ml− 1) 707 245 484 559 508 445 579 600 102
CRP (mg l− 1)d 16 16 23 11 11 10 12 7 10
Total proteins (g dl− 1) 6.9 7 7.4 7.7 7.8 7.6 7.7 7.5 7.3
Albumin (g dl− 1) 2.9 3.35 3.3 3.7 3.7 3.92 4 3.9 3.8
Total cholesterol (mg dl− 1) 285 190 177 164 151 145 140 146 127
Triglycerides (mg dl− 1) 216 168 102 129 107 130 176 155 151
LDL cholesterol (mg dl− 1) 199 122 121 101 99 88 77 87 71
HDL cholesterol (mg dl− 1) 43 34 36 37 31 31 28 28 28
Lynphocytes per mm3 1584 1711 1480 1500 1500 1550 1712 1891 1920
Transferrine (mg dl− 1) 281 216 240 261 225 245 262 247 254
Uric Acid (mg dl− 1) 9.8 6.5 5.8 7.2 8 8.5 8.3 8.1 7.1
HbA1c (%) 6.5 6.3 6.2 6.4 6.3 6 6.4 6.4 6.5
Hb (g dl− 1) 12 9.3 10.6 11.2 11 10.4 11.8 13.8 14
EPO (U kg− 1 per week) — 104 107 110 35 39 13.7 — —
ERI (U kg− 1 per week)/Hb — 11 10 9.8 3.2 3.7 1.2 — —
Abbreviations: BUN, blood urea nitrogen; CKD, chronic kidney disease; Crs, serum creatinine; eGFR, estimated glomerular ﬁltration rate; EPO, erythropoietin; ERI,
erythropoietin resistance index; GFR, glomerular ﬁltration rate; Hb, hemoglobin; HbA1c, glycated hemoglobin; HD, hemodialysis; HDL, high-density lipoprotein;
LDL, low-density lipoprotein; PTH, parathyroid hormone. aGFR: measured as the average of creatinine clearance and urea clearance, and expressed as ml/min*1.73
m2 body surface area. bEstimated by CKD-EPI formula. cEstimated by Modiﬁcation of Diet in Renal Disease (MDRD) formula. dCRP normal value ⩽ 10.
Morbid obesity in chronic kidney disease
S Caria et al
2
Nutrition & Diabetes (2016) 1 – 4
sufﬁcient to justify the weight loss registered, particularly as when
the patient weighed 219 kg she was not successful in adhering to
a series of low-calorie diets, and was moreover unable to
undertake physical exercise. As previously reported by Teplan V
et al.,9 the major contribution to the patient’s weight loss was
provided by AAs, which the patient received in high doses. These
compounds ensure a correct protein intake, increase only lean
body mass, reduce insulin resistance by increasing activity of the
cellular glucose transporter GLUT4 (which reduces blood glucose
levels by acting in an insulin-independent manner), and increase
the utilization of lipid and glucose substrates.10–15 AAs moreover
increase the production of adiponectin, leading in turn to a rise in
insulin sensitivity.16,17 According to the literature, the use of AAs in
our patient caused a sharp reduction in the need for exogenous
insulin, whereas increasing the efﬁciency of endogenous insulin,
as had already been observed in patients in highly critical
conditions.18 In the particular AAs mixture formulation adminis-
tered, the branched chain amino acids (BCAA) make up about 50%
of total AAs. The resulting BCAA blood increase activates beta-
oxidation, which enables the utilization of lipids for energy.19
Indeed, AAs regulate carbohydrate and fat metabolisms, thus
contributing towards maintaining the basal metabolism by
reducing fatty acid synthesis in the cytoplasm and providing for
an augmented access into the mitochondria.20 Leucine, which the
patient received at high doses (13.75 ± g per day), is essential for
the promotion of protein anabolism and inhibition of their
catabolism,21–23 and reduces appetite at the level of the
hypothalamus.24 Our patient indeed conﬁrmed that she had
experienced a reduction in the sensation of hunger. In our
opinion, the above-mentioned characteristics of AAs account for
the remarkable weight reduction observed. In the patient, high
doses of AAs met nitrogen requirements by minimizing urea
synthesis due to the absence of arginine into the amino acids
formulation, provided for an adequate caloric intake and
produced a good nitrogen balance throughout the observation
period, without eliciting protein catabolism. During the follow-up
period, BUN remained within an acceptable range (Table 1); this
depended both on the fact that a signiﬁcant part of the produced
azotemia was due to the inclusion of arginine in the patient’s diet,
and the improved action of non-essential amino acids on protein
biosynthesis which, due to the high levels of AAs, was not
catabolized into urea.25
Nevertheless, the progression of CKD was unfavorable; even
though a good metabolic balance was achieved, residual kidney
function gradually but progressively decreased (−0.4 ml min− 1 per
month). This may have been due to a series of factors such as
severe arterial hypertension, diabetes, obesity, persistent inﬂam-
matory status, high proteinuria and/or a potentially undiagnosed
additional renal disease.26
Dyslipidemia improved with a progressive reduction of
low-density lipoprotein (Table 1), in spite of the patient not
receiving statins; this effect may likewise have been the result of
both diet and AAs supplementation.27 Serum phosphate levels
were well controlled throughout the observation period, due to
the lack of phosphate in the AAs mixture. Severe SHPT persisted
and was treated with paricalcitol 2.0 mcg per day during
conservative therapy and 2.6 ± 0.6 mcg per day during dialysis;
after 40 months chronic renal disease-mineral bone disorders
therapy had produced a decrease in intact parathyroid hormone
to 102 pg ml− 1 (Table 1). Anemia improved progressively, and
ultimately the administration of erythropoietin was discontinued
(Table 1). During the 20 months of dialysis, the patient did
not contract any infections, CRP remained at lower levels
compared with the conservative phase (CRP 10.4 ± 1.7
versus 17.4 ± 3.9 mg l− 1), whereas albumin levels stabilized
(3.89 ± 0.12 g d l− 1). Administration of antihypertensive drugs
was discontinued a few months after commencing HD in view
of improved interdialytic weight loss (average 3.0% of body
weight), progressively extended duration of dialysis session, and
better modulation of dialysate sodium, assessed on the basis of
blood pressure levels ranging between 140–142 mmol l− 1. During
the conservative phase, the patient received 300 mg die− 1 of
allopurinol, although she failed to achieve target values of uric
acid (Table 1). In spite of the difﬁculties encountered in achieving
a good dialysis efﬁciency, high-protein intake (respect to the
conservative phase) and discontinuation of allopurinol at start of
dialysis, uric acid levels decreased gradually, reaching values of
7.1 mg d l− 1 in the 40th month (Table 1). It might be expected,
therefore a possible role of the AAs, probably when taken
continuously over a long period of time in the inhibition of the
synthesis of uric acid.
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Figure 1. Anthropometric parameters.
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At the end of the follow-up period, the patient’s quality of life
had improved remarkably, and she was able to walk indepen-
dently again. The patient had showed a good compliance in
following the diet and taking AAs. The patient has recently
been moved to the plastic surgery unit to undergo remodeling of
the abdomen with removal of all fat deposits, with an estimated
weight loss of an additional 30 kg approximately. The goal
is to achieve an overall weight loss of 130 kg (from 219 kg to
89 kg).
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